What is MOTS-c?
MOTS-c is a short peptide encoded in mitochondrial DNA, the small genome inside the cell's energy-producing mitochondria. It is studied for how cells handle glucose and respond to exercise. Most of the research is in cells and animals, and human data are early.
These articles cover where MOTS-c came from, what the studies measured, side effects, and how it compares with related peptides. Compounded MOTS-c is not FDA-approved and is prescription-only: a licensed provider reviews every request, and not everyone qualifies.
19 articles on this topic
-
MOTS-c Anti Aging: Human Benefits Remain Unproven
MOTS-c has not been shown to slow aging in people. Mouse findings and human blood measurements answer narrower questions about aging.
-
Should I Take MOTS-c? Start With These Questions
MOTS-c isn't an established treatment for weight loss or tiredness. A provider weighs the thin human evidence, your medicines and sports rules before deciding whether it fits.
-
MOTS-c News Update: September 2026
July's FDA advisory vote was the quarter's headline, but no rule has followed it. Here is what changed for MOTS-c from June to September, and what did not.
-
MOTS-c Exercise Claims: What the Studies Show
MOTS-c is called an exercise mimetic because exercise raises it in people and administered MOTS-c changed running performance in mice. No published human trial shows that taking it improves a workout.
-
Who Discovered MOTS-c? The 2015 USC Discovery
Changhan Lee, Pinchas Cohen, and their colleagues reported MOTS-c in 2015. Its history runs from an overlooked genetic sequence to human observations and an ongoing question about treatment.
-
MOTS-c and Retatrutide: No Evidence for a Stack
No published study has tested MOTS-c and retatrutide together. Retatrutide cannot be compounded for patient care, while MOTS-c is a separate prescription discussion with much thinner human evidence.
-
MOTS-c for Weight Loss: Human Evidence Is Thin
Mouse studies are interesting, but no completed randomized trial shows that MOTS-c causes weight loss in people. Human studies so far mostly measure the peptide already in the body.
-
MOTS-c Tablets: No Human Evidence Supports Them
MOTS-c tablets have no published human absorption data. The studies behind the peptide used injected animals or measured the MOTS-c people made themselves.
-
MOTS-c vs Tesamorelin: Not a Fat-Loss Contest
MOTS-c and tesamorelin work through different systems, and their evidence is not comparable. Tesamorelin has large late-stage trials for one narrow HIV-related condition; MOTS-c does not yet have completed human treatment results.
-
MOTS-c Before and After: What Research Shows
MOTS-c before and after photos are not clinical evidence. Human research has measured exercise and metabolic markers, but no completed study has published visible results from giving native MOTS-c—the exact peptide, not an altered analogue—to people.
-
Where to Inject MOTS-c: What the Evidence Says
The available human trial records point to a subcutaneous shot into the fatty layer beneath the skin. The pharmacy label and prescriber—not an online injection map—set the site for a specific MOTS-c preparation.
-
SS-31 and MOTS-c: Can You Take Them Together?
They are both mitochondrial peptides, and that is about where the similarity stops. No published trial has given people both at once — here is what each one has behind it.
-
When to Take MOTS-c: What Human Research Says
No human trial has shown that morning, night, or a workout window is best. The exercise link is real but easy to overread: researchers measured the MOTS-c people made themselves, not the effect of a timed dose.
-
MOTS-c Cycle: Nobody Has Established One
The word “cycle” came from bodybuilding, not from any MOTS-c research. Every study that has actually given the peptide — the mouse work, and the one human trial now running — dosed it straight through, with no weeks off.
-
MOTS-c Half-Life: What Is Actually Known
No published study has measured how long the body takes to clear a dose of MOTS-c. Here is what the rodent work, the exercise data and one unpublished Phase 1 trial actually show.
-
Peptides for Insulin Resistance: Evidence
The evidence runs from large clinical trials for semaglutide and tirzepatide to animal and observational research for MOTS-c. Those are not interchangeable levels of certainty.
-
MOTS-c Side Effects: What Is Known and What Is Not
No completed human trial has measured them. What gets sold as a MOTS-c side-effect profile is assembled from injection-site experience with subcutaneous peptides, from pharmacology, and from what a prescriber screens for.
-
MOTS-c Dosage: Why There Is No Standard Dose
There is no established human MOTS-c dose. Published human research is mostly observational, and the numbers repeated online come largely from mouse experiments rather than clinical dosing trials.
-
MOTS-c Peptide Benefits: Rodent Depth, Human Hints
MOTS-c is a peptide your mitochondria encode themselves — and it is studied for how cells handle fuel. The rodent evidence runs deep; the human evidence is just beginning.